

Claims

6. An antiviral liquid drug presented as nasal
5 drops comprising an interferon and a biocompatible
polymer wherein the interferon component is a
genetically engineered interferon alpha, beta or gamma,
and the drug viscosity is 11 - 300 Pa*s.

7. The antiviral drug of claim 6, further
10 comprising an antioxidant.

8. The antiviral drug of claim 7, wherein the
interferon, biocompatible polymer and antioxidant are
contained in the following amounts per ml buffer
mixture:

15 Genetically engineered interferon 1,000 - 500,000

IU

Biocompatible polymer 0.005 - 0.714 g

Antioxidant 0.0001 - 0.0008 g

9. The antiviral drug of claim 7, wherein the
20 antioxidant is Trilon B.

10. The antiviral drug of claim 7, wherein the
biocompatible polymer is polyvinylpyrrolidone.

11. The antiviral drug of claim 7, wherein the
biocompatible polymer is polyethylene oxide.

25 12. The antiviral drug of claim 7, wherein the
biocompatible polymer is a combination of
polyvinylpyrrolidone and polyethylene oxide.

13. The antiviral drug of claim 12, wherein the
polyvinylpyrrolidone to polyethylene oxide ratio is 1:1
30 to 1:50.